Chemotherapy of Cutaneous Leishmaniasis
Abstract
Two antileishmanial test systems (MLS and MLL) were used to evaluate compounds at one or more levels. These test systems used female BALB/c mice infected with Leishmania major. There were 11 MLS tests done and 242 compounds used. The following 19 compounds were active; BU55197, BU5504,BP20206, BQ90098, BQ90552, BS81946, BS83191, BS86085,BU30118, BQ90981, BQ92145, AQ52825, BS04930, BS80690, BS93553, BU26730, BU59640, BS84858 and BU68416. In the MLS test parasites were injected intradermally (ID) at the base of the tail. Drug treatment was started on day 3 post infection IP for 10 days. In addition, 13 MLL tests were done and 113 compounds used. Results indicated 4 actives: BG32694,BU59640, BU59640 and BU68452. In the MLL test, mice were infected ID at the base of the tail and treatment was started IP for 10 days when the lesions reached between 20-70 mm2. AmBiosome was used as the positive control for all test systems. The Oracle database was used for tabulation of data and statistically analyzing the results.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- AD1017714
Entities
People
- Arba Ager
Organizations
- University of Miami